ClinicaliQ Trial Snapshot
- A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn’s Disease — Recruiting • Phase III • Rheumatology • NCT07499232.
- What is being tested: A head-to-head comparison of two IL-23 inhibitor monoclonal antibodies—guselkumab and risankizumab—to evaluate their efficacy and safety in treating moderately to severely active Crohn's Disease.
- Patient eligibility overview: The trial recruits adults with confirmed moderately to severely active Crohn's Disease; specific inclusion criteria typically require documented disease activity, confirmed diagnosis, and may exclude patients with prior exposure to certain biologics or those with severe comorbidities.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to assess how well guselkumab works when compared to risankizumab in participants with moderately to severely active Crohn's Disease (CD; a long-term condition causing severe inflammation of the intestinal tract).
Eligibility Snapshot
- : * Has CD or fistulizing Crohn's Disease (CD) of at least 12 weeks' duration, with colitis, ileitis, or ileocolitis, confirmed at some time in the past by radiography, histology, and/or endoscopy * Have moderately to severely active CD, defined as baseline Crohn's Disease Activity Index (CDAI) score greater than or equal to (>=) 220 but less than or equal to (
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.